Leflunomida Normon

Leflunomide, the active ingredient in Leflunomida Normon, is a disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for oral use. It is prescribed to reduce inflammation and halt disease progression in adults with rheumatoid arthritis and psoriatic arthritis, acting as an immunomodulatory agent that suppresses abnormal immune activity.

GNH USA supplies Leflunomida Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Leflunomide is a DMARD that modulates immune activity in inflammatory joint diseases.

- Rheumatoid arthritis: reduces joint inflammation, pain, and structural damage, improving functional ability. - Psoriatic arthritis: alleviates joint swelling and skin lesions, helping maintain mobility and quality of life.

Leflunomide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild gastrointestinal upset. - Nausea: feeling of sickness. - Elevated liver enzymes: transient increase in hepatic transaminases. - Hypertension: rise in blood pressure. - Hair loss: thinning of scalp hair. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Infections: opportunistic or serious bacterial infections. - Vasculitis: inflammation of blood vessels.

When prescribing Leflunomida Normon, clinicians should observe several safety considerations.

- Pregnancy: contraindicated; avoid use in women of childbearing potential. - Liver function: monitor hepatic enzymes before and during therapy. - Hematology: perform regular complete blood counts to detect bone‑marrow suppression. - Blood pressure: assess and control hypertension prior to initiation. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Leflunomide can influence the activity of other medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Teriflunomide: additive toxicity; concurrent use should be avoided.

Moderate Interactions (Monitor Closely): - Methotrexate: enhanced hepatotoxicity; monitor liver enzymes. - Statins (e.g., simvastatin): increased risk of myopathy; watch for muscle symptoms. - Live vaccines: reduced efficacy and potential infection; avoid administration during therapy.